1313 related articles for article (PubMed ID: 34086881)
1. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
2. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
Johnston MS; Galan A; Watsky KL; Little AJ
JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan.
Higashino T; Yamazaki Y; Senda S; Satou Y; Yonekura Y; Imai K; Arakawa J; Kawano S; Horinosono H; Miura Y
JAMA Dermatol; 2022 Aug; 158(8):923-927. PubMed ID: 35649530
[TBL] [Abstract][Full Text] [Related]
5. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
6. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
10. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
Front Public Health; 2022; 10():975781. PubMed ID: 36238255
[TBL] [Abstract][Full Text] [Related]
11. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction.
Hoff NP; Freise NF; Schmidt AG; Firouzi-Memarpuri P; Reifenberger J; Luedde T; Bölke E; Meller S; Homey B; Feldt T; Jensen BEO; Keitel V; Schmidt L; Maas K; Haussmann J; Tamaskovics B; Budach W; Fischer JC; Buhren BA; Knoefel WT; Schneider M; Gerber PA; Pedoto A; Häussinger D; Grebe O; van Griensven M; Braun SA; Salzmann S; Rezazadeh A; Matuschek C
Eur J Med Res; 2021 Aug; 26(1):98. PubMed ID: 34433495
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
13. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.
Naveed Z; Li J; Spencer M; Wilton J; Naus M; García HAV; Otterstatter M; Janjua NZ
CMAJ; 2022 Nov; 194(45):E1529-E1536. PubMed ID: 36410749
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
[TBL] [Abstract][Full Text] [Related]
15. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
17. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
[TBL] [Abstract][Full Text] [Related]
18. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria.
Kamura Y; Sakamoto T; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Chiba S; Obara N
Int J Hematol; 2022 Jul; 116(1):55-59. PubMed ID: 35668275
[TBL] [Abstract][Full Text] [Related]
19. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.
Mangat HS; Musah A; Luedtke S; Syed AA; Maramattom BV; Maruthanal J; Bosman A; Kostkova P
Front Public Health; 2022; 10():972464. PubMed ID: 36311588
[TBL] [Abstract][Full Text] [Related]
20. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
Kadali RAK; Janagama R; Peruru S; Gajula V; Madathala RR; Chennaiahgari N; Malayala SV
J Med Virol; 2021 Jul; 93(7):4420-4429. PubMed ID: 33822361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
